Inducible pluripotent stem cells: Not quite ready for prime time?

Reiesha D. Robbins, Nutan Prasain, Bernhard Maier, Mervin Yoder, Raghu Mirmira

Research output: Contribution to journalArticle

26 Citations (Scopus)


Purpose of review: Inducible pluripotent stem (iPS) cells derived from somatic cells represent a novel renewable source of tissue precursors. The potential of iPS cells is considered to be at least equivalent to that of human embryonic stem cells, facilitating the treatment or cure of diseases such as diabetes mellitus, spinal cord injuries, cardiovascular disease, and neurodegenerative diseases, but with the potential added benefit of evading the adaptive immune response that otherwise limits allogeneic cell-based therapies. This review discusses recent advances in pluripotency induction and the use of iPS cells to produce differentiated cells, while highlighting roadblocks to the widespread use of this technology in the clinical arena. Recent findings: Whereas ethical and safety issues surrounding the use of human embryonic stem cells for the treatment of disease continue to be debated, use of iPS cells may be viewed as a more widely acceptable compromise. Since the first descriptions of inducible pluripotency from somatic cells, multiple laboratories have collectively made tremendous strides both in developing alternative, more clinically acceptable, induction strategies and in demonstrating the proof-of-principle that iPS cells can be differentiated into a variety of cell types to reverse mouse models of human disease. Summary: Although the prospect of using patient-specific iPS cells has much appeal from an ethical and immunologic perspective, the limitations of the technology from the standpoint of reprogramming efficiency and therapeutic safety necessitate much more in-depth research before the initiation of human clinical trials.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalCurrent Opinion in Organ Transplantation
Issue number1
StatePublished - Feb 2010


Pluripotent Stem Cells
Adaptive Immunity
Cell- and Tissue-Based Therapy
Spinal Cord Injuries
Neurodegenerative Diseases
Diabetes Mellitus
Cardiovascular Diseases
Clinical Trials


  • Induced pluripotency
  • Regenerative medicine
  • Somatic reprogramming
  • Stem cells
  • Tissue engineering

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this

Inducible pluripotent stem cells : Not quite ready for prime time? / Robbins, Reiesha D.; Prasain, Nutan; Maier, Bernhard; Yoder, Mervin; Mirmira, Raghu.

In: Current Opinion in Organ Transplantation, Vol. 15, No. 1, 02.2010, p. 61-67.

Research output: Contribution to journalArticle

title = "Inducible pluripotent stem cells: Not quite ready for prime time?",
abstract = "Lippincott Williams & Wilkins.",
keywords = "Induced pluripotency, Regenerative medicine, Somatic reprogramming, Stem cells, Tissue engineering",
author = "Robbins, {Reiesha D.} and Nutan Prasain and Bernhard Maier and Mervin Yoder and Raghu Mirmira",
year = "2010",
month = "2",
doi = "10.1097/MOT.0b013e3283337196",
language = "English",
volume = "15",
pages = "61--67",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "1",



T1 - Inducible pluripotent stem cells

T2 - Not quite ready for prime time?

AU - Robbins, Reiesha D.

AU - Prasain, Nutan

AU - Maier, Bernhard

AU - Yoder, Mervin

AU - Mirmira, Raghu

PY - 2010/2

Y1 - 2010/2

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - Induced pluripotency

KW - Regenerative medicine

KW - Somatic reprogramming

KW - Stem cells

KW - Tissue engineering

UR -

UR -

U2 - 10.1097/MOT.0b013e3283337196

DO - 10.1097/MOT.0b013e3283337196

M3 - Article

C2 - 19855280

AN - SCOPUS:75749142357

VL - 15

SP - 61

EP - 67

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 1

ER -